Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies

Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies

The COVID-19 mortality is associated with an increase in interleukin-6 (IL-6) levels. Levilimab is an anti–IL-6 receptor antibody with proven clinical efficacy in patients with severe COVID-19.The aim of the study was to assess the association of COVID-19 severity and levilimab effectiveness with IL...

Full description

Bibliographic Details
Main Authors: N. V. Lomakin, B. A. Bakirov, G. H. Musaev, V. V. Popov, E. A. Smolyarchuk, Yu. N. Linkova, D. V. Bogdan, A. V. Eremeeva, P. S. Pukhtinskaia, M. A. Morozova, A. V. Zinkina-Orikhan, A. A. Lutckii
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-12-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
levilimab
covid-19
interleukin-6
cytokine release syndrome
acute respiratory distress syndrome
hyperinflammatory syndrome
pathogenesis-oriented therapy
Online Access:https://www.biopreparations.ru/jour/article/view/443

Internet

https://www.biopreparations.ru/jour/article/view/443

Similar Items